Roth Capital Has Negative Outlook for MGRM Q3 Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings per share (EPS) estimate for Monogram Orthopaedics to ($0.18), down from a prior estimate of ($0.13).
• Monogram Orthopaedics' stock opened at $5.46, with a 52-week low of $1.92 and a high of $6.02.
• A range of institutional investors have increased their stakes in Monogram Orthopaedics, indicating a growing interest despite the recent earnings miss.

Monogram Orthopaedics Inc. (NASDAQ:MGRM - Free Report) - Equities research analysts at Roth Capital lowered their Q3 2025 earnings per share estimates for Monogram Orthopaedics in a research note issued to investors on Tuesday, August 19th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.18) per share for the quarter, down from their prior forecast of ($0.13). The consensus estimate for Monogram Orthopaedics' current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at $0.21 EPS.

Monogram Orthopaedics Trading Down 0.2%

NASDAQ MGRM traded down $0.01 during trading on Friday, hitting $5.45. 76,767 shares of the company traded hands, compared to its average volume of 175,125. The business has a fifty day simple moving average of $4.52 and a 200 day simple moving average of $3.30. The company has a market capitalization of $221.43 million, a P/E ratio of -10.90 and a beta of 0.69. Monogram Orthopaedics has a 12 month low of $1.92 and a 12 month high of $6.02.

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last announced its quarterly earnings data on Friday, August 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05).

Institutional Investors Weigh In On Monogram Orthopaedics

A number of institutional investors have recently added to or reduced their stakes in the company. Crestwood Advisors Group LLC acquired a new stake in Monogram Orthopaedics during the second quarter valued at approximately $29,000. Jane Street Group LLC boosted its holdings in Monogram Orthopaedics by 83.0% during the first quarter. Jane Street Group LLC now owns 19,426 shares of the company's stock valued at $57,000 after purchasing an additional 8,810 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its holdings in Monogram Orthopaedics by 6.1% during the first quarter. Focus Partners Advisor Solutions LLC now owns 213,678 shares of the company's stock valued at $628,000 after purchasing an additional 12,328 shares in the last quarter. Northern Trust Corp boosted its holdings in Monogram Orthopaedics by 110.6% during the fourth quarter. Northern Trust Corp now owns 45,873 shares of the company's stock valued at $109,000 after purchasing an additional 24,088 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Monogram Orthopaedics by 286.6% during the fourth quarter. Wells Fargo & Company MN now owns 11,597 shares of the company's stock valued at $27,000 after purchasing an additional 8,597 shares in the last quarter. 0.45% of the stock is owned by institutional investors and hedge funds.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.